2022
DOI: 10.3390/cancers14163918
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target

Abstract: Tumour molecular annotation is mandatory for biomarker discovery and personalised approaches, particularly in triple-negative breast cancer (TNBC) lacking effective treatment options. In this study, the interleukin-3 receptor α (IL-3Rα) was investigated as a prognostic biomarker and therapeutic target in TNBC. IL-3Rα expression and patients’ clinical and pathological features were retrospectively analysed in 421 TNBC patients. IL-3Rα was expressed in 69% human TNBC samples, and its expression was associated wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 59 publications
(72 reference statements)
0
1
0
Order By: Relevance
“…We speculate that this may be a reason why ACE2 is upregulated in inflamed tumors, especially in TNBC. Moreover, TNBC expressed higher PD-L1, which is the suitable subtype for the study of anti-tumor immunity in BC [41,42]. Thus, the role of ACE2 in regulating anti-tumor immunity in TNBC should be given particular attention.…”
Section: Discussionmentioning
confidence: 99%
“…We speculate that this may be a reason why ACE2 is upregulated in inflamed tumors, especially in TNBC. Moreover, TNBC expressed higher PD-L1, which is the suitable subtype for the study of anti-tumor immunity in BC [41,42]. Thus, the role of ACE2 in regulating anti-tumor immunity in TNBC should be given particular attention.…”
Section: Discussionmentioning
confidence: 99%